8-K current report · filed Nov 4, 2026

Progyny, Inc. (PGNY) 8-K Current Report: November 4, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2PGNY overview

Short answer

Progyny, Inc. (PGNY) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 results announced for quarter ended September 30, 2026.

Progyny, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Supplemental earnings presentation available through Progyny’s investor relations website
  • Investors should review Exhibits 99.1 and 99.2 for financial results and management commentary

Item 7.01 · Regulation FD Disclosure

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Supplemental earnings presentation available through Progyny’s investor relations website
  • Investors should review Exhibits 99.1 and 99.2 for operating and financial details

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $341.3M, up 8.9%, with fertility services up 10.6% and pharmacy services up 5.8%
  • Gross margin improved to 24.5% from 23.2%; net income nearly doubled to $26.3M, or $0.32 diluted EPS
  • Record selling season added 1.3M covered lives and over 85 clients, while 2027 retention remained near 100%
  • Nearly 11M shares repurchased in 2026, including nearly 3M during Q3 for $82.7M, reducing diluted share count
  • Full-year revenue midpoint raised to $1.375B and Adjusted EBITDA midpoint to $237.5M, with $195.6M liquidity and no debt

Item EX-99.2 · Exhibit EX-99.2

  • 3Q revenue $341.3M, up 8.9%, driven by client and covered-life growth
  • Gross profit rose 15% to $83.7M, with gross margin expanding 130 basis points to 24.5%
  • Adjusted EBITDA increased 6.3% to $58.4M, but margin declined 40 basis points to 17.1% amid platform investments
  • Operating cash flow reached $56.6M, while cash and marketable securities totaled $196M with no debt
  • 2026 guidance maintained: revenue $1.365B-$1.385B and Adjusted EBITDA $235M-$240M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Progyny, Inc. 8-K filings

Get the next PGNY 8-K as it lands

Follow PGNY for push alerts, or ask the research agent what this filing means.